Georgia's Online Cancer Information Center

Find A Clinical Trial

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Status
Active
Cancer Type
Breast Cancer
Colon/Rectal Cancer
Head and Neck Cancer
Liver Cancer / Hepatoblastoma
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Sarcoma
Stomach/ Gastric Cancer
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04140526
Protocol IDs
ONC-392-001 (primary)
NCI-2020-06149
20193108
4R44CA250824-02
R44CA250824-01
Study Sponsor
OncoC4, Inc.

Summary

This is a First-in-Human Phase IA/IB open label dose escalation study of intravenous (IV)
administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent
and in combination with pembrolizumab in participants with advanced or metastatic solid
tumors and non-small cell lung cancers.

Objectives

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of
differentiation 152), is a cell surface protein receptor that interacts with B7-1 (CD80) and
B7-2 (CD86) to ensure proper function of regulatory T cells and protect host against
autoinflammatory diseases. Anti-CTLA-4 monoclonal antibodies (mAbs) have demonstrated strong
and broad cancer immunotherapeutic effects (CITE) in a variety of preclinical models and are
used clinically both as monotherapy and as part of combination therapy with Nivolumab
(anti-PD-1). However, CTLA-4 monotherapy has more immunotherapy-related adverse effects
(irAEs) than anti-PD-1/PD-L1 therapy. In addition, the rate of severe irAE (Grades 3 and 4)
reached 55% in melanoma patients receiving combination of Ipilimumab and Nivolumab. The
strong irAEs further limit the doses tolerated by cancer patients. Nevertheless, combination
with anti-PD-1 resulted in significantly improved response rates and patient survival in
multiple types of cancer. Furthermore, anti-CTLA-4 antibodies induce long-lasting immunity in
cancer patients. Therefore, CTLA-4 remains an important immunotherapy target, but major
challenges remain in improving both safety and efficacy of anti-CTLA-4 mAbs.

ONC-392 is a highly selective, humanized monoclonal IgG1-kappa isotype antibody against
CTLA-4. The parental clone was identified through in vivo screening in humanized CTLA-4 mouse
model for high anti-tumor efficacy and low autoimmune toxicity. We have recently demonstrated
that ONC-392 is dissociation from CTLA-4 under low pH to allow its escape from lysosomal
degradation and recycle to cell surface. We have provided several lines of evidence for the
notion that a pH-sensitive antibody ONC-392 is not only safer but also more effective in Treg
depletion and tumor rejection than the Ipilimumab, which is pH-insensitive. First, by
preserving CTLA-4 on the cell surface, Onc-392 leaves higher ligand density for better ADCC.

Second, Onc-392 is more efficient in Treg depletion in tumor microenvironment. Third, Onc-392
is significantly more potent in inducing rejection of large tumors.

The study consists of three parts:

(1) The Part A study is a dose-finding rapid titration, Phase I trial of ONC-392 as a single
agent in patients with advanced or metastatic solid tumors with various histology. The aim of
this trial is to define the recommended Phase II dose for ONC-392 monotherapy (RP2D-M). (2)
The Part B study is a dose-finding phase in combination therapies. Part B1 is ONC-392 in
combination with a standard dose of 200 mg pembrolizumab in patients with advanced or
metastatic solid tumors. Part B2 is ONC-392 in combination with a standard dose of oral TKI
Osimertinib in patients with non small cell lung cancer with EGFR mutations.

(3) The Part C consists of 13 different expansion arms.

1. Arm A: Pancreatic Cancer Cohort, ONC-392 monotherapy, will enroll advanced/metastatic
pancreatic cancer patients who have progressive disease after first and second lines of
systemic treatment.

2. Arm B: TNBC Cohort, ONC-392 monotherapy, will enroll advanced/metastatic TNBC patients
who have progressive disease after prior systemic treatments, including checkpoint
inhibitor immunotherapy.

3. Arm C: NSCLC Mono Cohort 1, ONC-392 monotherapy, will enroll advanced/metastatic NSCLC
patients with EGFR or ALK mutations who have progressive disease after prior systemic
treatments, including targeted therapy or checkpoint inhibitors.

4. Arm D: NSCLC IO Naïve Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic NSCLC cancer patients who are treatment naïve, or anti PD (L)1
immunotherapy naïve and PD-L1-positive (PD L1 TPS = 1%).

5. Arm E: NSCLC IO R/R Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic NSCLC cancer patients who are R/R to prior anti-PD-(L)1
immunotherapy regardless of PD-L1 status and with disease progression with ONC-392
monotherapy from Arm C or Arm I.

6. Arm F: Melanoma IO Naïve Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic Melanoma patients who are treatment naïve, or checkpoint inhibitor
immunotherapy naive. Prior systemic chemotherapy or targeted therapy are allowed.

7. Arm G: Melanoma IO R/R Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic melanoma patients who are R/R to anti-PD-(L)1 immunotherapy and
progressed with ONC-392 monotherapy from Arm J.

8. Arm H: MCC IO R/R Cohort, ONC-392 monotherapy therapy will enroll advanced/metastatic
MCC patients who are R/R to prior immunotherapy or experience cancer recurrence within 1
year of IO adjuvant treatment.

9. Arm I: NSCLC Mono Cohort 2, ONC-392 monotherapy, will enroll advanced/metastatic NSCLC
patients without EGFR or ALK mutations who have progressive disease after prior systemic
treatments, including chemotherapy or checkpoint inhibitors. Patient must have
anti-PD-(L)1 treatment, either alone or in combination, as last treatment before
enrollment. Prior anti-CTLA-4 treatment is allowed.

10. Arm J: Melanoma Mono Cohort, ONC-392 monotherapy, will enroll advanced/metastatic
melanoma patients with or without BRAF mutations who have progressive disease after
prior systemic treatments, including targeted therapy or checkpoint inhibitors. Patient
must have anti-PD-(L)1 treatment, either alone or in combination, as last treatment
before enrollment. Prior anti-CTLA-4 treatment is allowed.

11. Arm K: Head and Neck Squamous Cell Carcinoma (HNSCC), ONC-392 monotherapy, will enroll
advanced/metastatic HNSCC patients with or without positive HPV who have progressive
disease after prior systemic treatments, including chemotherapy or checkpoint
inhibitors. Patient must have anti-PD-(L)1 treatment, either alone or in combination, as
last treatment before enrollment.

12. Arm L: Ovarian Cancer, ONC-392 monotherapy, will enroll patients with
advanced/metastatic ovarian cancer who have progressive disease after prior systemic
treatments, including chemotherapy, targeted therapy or checkpoint inhibitors.

13. Arm M: Solid Tumors, ONC-392 monotherapy, will enroll patients with advanced/metastatic
solid tumors who are not eligible for Arm A-C or H-L, who have progressive disease after
prior systemic treatments, including chemotherapy, targeted therapy or checkpoint
inhibitors.

Eligibility

  1. Inclusion Criteria: 1. . Patients must have a histological or cytological diagnosis of NSCLC or any other type of carcinoma or sarcomas, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy. 1. In the Part A Phase I dose escalation study of ONC-392 monotherapy, patients with advanced/metastatic solid tumors of any histology are eligible for participation. Please note: tumor types of primary interest in this study are malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, colorectal cancer, any type of sarcoma. 2. In Part B1 dose finding of the ONC-392 plus pembrolizumab combination, patients with advanced/metastatic solid tumors of any histology that Pembrolizumab has been approval as standard of care are eligible for participation. Part B2 is for patients with non small cell lung cancer with EGFR mutations. 3. In Part C, patients with pancreatic cancer, triple negative breast cancer, non small cell lung cancer, melanoma, Merkel cell carcinoma, Head and Neck cancer, ovarian cancer, and other solid tumors are eligible. 4. Measurable disease: i. In Phase IA dose-finding studies (trial A and B), patients may have non-measurable disease. ii. In Phase IB expansion cohorts, patients must have measurable disease as defined per RECIST version 1.1: iii. Tumor mass: Must be accurately measurable in at least 1 dimension (longest diameter to be recorded) with a minimum size of: 1. 10 mm by computed tomography (CT) scan (CT scan slide thickness must be <5 mm), 2. 20 mm by chest X-ray (if clearly defined and surrounded by aerated lung). iv. Malignant lymph nodes: >15 mm in short axis when assessed by CT scan (CT scan slice thickness must be <5 mm). 2. Patient is male or female and >18 years of age on day of signing informed consent. 3. Patient must have a performance status of = 2 on the ECOG Performance Scale 4. Patient must have adequate organ function as indicated by the following laboratory values: Hematological: Absolute neutrophil count (ANC) =1,500 /mcL; Plateletsa =100,000 / mcL; Hemoglobin =9 g/dL or =5.6 mmol/L- without qualifications; Renal: Serum creatinine =1.5 X upper limit of normal (ULN); Hepatic: Serum total bilirubin =1.5 X ULN; OR Direct bilirubin = ULN for patients with total bilirubin levels >1.5 ULN; AST (SGOT) and ALT (SGPT) =2.5 X ULN, OR =5 X ULN for patients with active liver metastases Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) =1.5 X ULN Activated Partial Thromboplastin Time (aPTT) =1.5 X ULN 5. Patient has voluntarily agreed to participate by giving written informed consent. 6. Female patient of childbearing potential has a negative urine or serum pregnancy test. 7. Female and Male patients must agree to use adequate methods of contraception starting with the first dose of study drug through 90 days after the last dose of study therapy. Exclusion Criteria: A patient meeting any of the following criteria is not eligible to participate in this study: 1. Patients who have not recovered to CTCAE = 1 from the AE due to cancer therapeutics. The washout period for cancer therapeutic drugs (such as chemotherapy, radioactive, or targeted therapy) is 21 days, and for antibody drug 28 days. 2. Patients who are currently enrolled in a clinical trial of an investigational agent or device. 3. Patients who are on chronic systemic steroid therapy at doses >10 mg/day 4. Patients who have active symptomatic brain metastasis or leptomeningeal metastasis. 5. Patients who have an active infection requiring systemic IV therapy within 14 days of prior to administration of ONC-392 or combined ONC-392 and Pembrolizumab. 6. Patients who have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator. 7. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 8. Patients who are pregnant or breastfeeding. 9. For the Part B1 and Part C Arm D to G, the patients that are deemed to be not suitable for Pembrolizumab.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.